Skip to main content

Pneumococcal Infectious Disease

7
Pipeline Programs
1
Companies
8
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
1
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
1100%
+ 7 programs with unclassified modality

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Sinovac Biotech
Sinovac BiotechChina - Beijing
8 programs
4
1
1
1
Sinovac PCV13Phase 31 trial
Sinovac PCV24Phase 21 trial
Sinovac Low-dosage PCV24Phase 1/21 trial
Sinovac PCV13Phase 11 trial
Sinovac PCV24Phase 11 trial
+3 more programs
Active Trials
NCT07071701Completed19,267Est. Apr 2024
NCT06183216Completed140Est. Mar 2025
NCT06800261Recruiting180Est. Jun 2026
+5 more trials

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
2027
Sinovac BiotechSinovac PCV13
Sinovac BiotechSinovac PCV24
Sinovac BiotechSinovac Low-dosage PCV24
Sinovac BiotechSinovac PCV24
Sinovac BiotechSinovac PCV24 formulation 1
Sinovac BiotechSinovac PCV24 formulation 1
Sinovac BiotechSinovac PCV13
Sinovac Biotech23-valent pneumococcal polysaccharide vaccine

Clinical Trials (8)

Total enrollment: 23,761 patients across 8 trials

NCT06617715Sinovac BiotechSinovac PCV13

Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine

Start: Oct 2024Est. completion: Jul 20263,080 patients
Phase 3Recruiting
NCT07300644Sinovac BiotechSinovac PCV24

Clinical Trial of PCV24 in Infants and Children Aged 2 Months to 5 Years

Start: Nov 2025Est. completion: Dec 2027420 patients
Phase 2Recruiting
NCT07543198Sinovac BiotechSinovac Low-dosage PCV24

Clinical Trial of PCV24 in Adults Aged ≥18 Years

Start: Jun 2025Est. completion: Feb 2026385 patients
Phase 1/2Completed
NCT06800261Sinovac BiotechSinovac PCV24

Clinical Trial of PCV24 in Infants Aged 2-23 Months

Start: May 2025Est. completion: Jun 2026180 patients
Phase 1Recruiting
NCT06550830Sinovac BiotechSinovac PCV24 formulation 1

Clinical Trial of PCV24 in Children Aged 2-17 Years

Start: Sep 2024Est. completion: Jun 2025119 patients
Phase 1Completed
NCT06474377Sinovac BiotechSinovac PCV24 formulation 1

Clinical Trial of PCV24 in Adults

Start: Jun 2024Est. completion: Feb 2025170 patients
Phase 1Completed
NCT06183216Sinovac BiotechSinovac PCV13

A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine

Start: Jan 2024Est. completion: Mar 2025140 patients
Phase 1Completed
NCT07071701Sinovac Biotech23-valent pneumococcal polysaccharide vaccine

A Clinical Trial to Observe the Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Target Population

Start: Jul 2022Est. completion: Apr 202419,267 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
3 actively recruiting trials targeting 23,761 patients
1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.